Roth Capital Comments on Zevra Therapeutics, Inc.’s Q2 2024 Earnings (NASDAQ:ZVRA)

Zevra Therapeutics, Inc. (NASDAQ:ZVRAFree Report) – Investment analysts at Roth Capital lowered their Q2 2024 earnings per share estimates for shares of Zevra Therapeutics in a note issued to investors on Wednesday, June 5th. Roth Capital analyst J. Aschoff now forecasts that the company will earn ($0.45) per share for the quarter, down from their previous forecast of ($0.44). The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.54) per share. Roth Capital also issued estimates for Zevra Therapeutics’ Q3 2024 earnings at ($0.42) EPS, FY2024 earnings at ($1.33) EPS, FY2025 earnings at ($0.25) EPS, FY2026 earnings at $0.93 EPS, FY2027 earnings at $1.92 EPS and FY2028 earnings at $2.40 EPS.

Zevra Therapeutics (NASDAQ:ZVRAGet Free Report) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.09. Zevra Therapeutics had a negative return on equity of 82.55% and a negative net margin of 181.76%. The business had revenue of $3.43 million for the quarter, compared to the consensus estimate of $3.52 million.

A number of other equities research analysts have also recently weighed in on the company. Maxim Group upped their price objective on Zevra Therapeutics from $12.00 to $18.00 and gave the stock a “buy” rating in a research note on Tuesday, April 2nd. William Blair restated an “outperform” rating on shares of Zevra Therapeutics in a research note on Tuesday, March 12th. Cantor Fitzgerald restated an “overweight” rating on shares of Zevra Therapeutics in a research note on Monday, April 1st. Finally, HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of Zevra Therapeutics in a research note on Wednesday, April 3rd. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $19.50.

Read Our Latest Stock Report on Zevra Therapeutics

Zevra Therapeutics Trading Down 1.5 %

Shares of NASDAQ ZVRA opened at $4.65 on Monday. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.10 and a quick ratio of 2.10. The stock has a market capitalization of $194.60 million, a P/E ratio of -3.44 and a beta of 1.96. Zevra Therapeutics has a 1-year low of $3.89 and a 1-year high of $7.28. The business has a fifty day moving average price of $4.76 and a 200 day moving average price of $5.44.

Institutional Trading of Zevra Therapeutics

Institutional investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC lifted its position in shares of Zevra Therapeutics by 134.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 9,673 shares of the company’s stock valued at $63,000 after acquiring an additional 5,545 shares in the last quarter. International Assets Investment Management LLC lifted its position in shares of Zevra Therapeutics by 555.0% in the fourth quarter. International Assets Investment Management LLC now owns 6,550 shares of the company’s stock valued at $43,000 after acquiring an additional 5,550 shares in the last quarter. IFG Advisors LLC lifted its position in shares of Zevra Therapeutics by 45.0% in the first quarter. IFG Advisors LLC now owns 18,700 shares of the company’s stock valued at $108,000 after acquiring an additional 5,800 shares in the last quarter. SG Americas Securities LLC lifted its position in shares of Zevra Therapeutics by 41.7% in the fourth quarter. SG Americas Securities LLC now owns 20,999 shares of the company’s stock valued at $138,000 after acquiring an additional 6,175 shares in the last quarter. Finally, VisionPoint Advisory Group LLC purchased a new position in Zevra Therapeutics during the third quarter worth approximately $33,000. 35.03% of the stock is owned by institutional investors and hedge funds.

Zevra Therapeutics Company Profile

(Get Free Report)

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.

Recommended Stories

Earnings History and Estimates for Zevra Therapeutics (NASDAQ:ZVRA)

Receive News & Ratings for Zevra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zevra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.